LeonaBio (LONA)
NASDAQ:LONA
Want to see LONA full AI Analyst Report?
Top Page
LeonaBio
(NASDAQ:LONA)
Select Model
Select Model
Rating:55Neutral
Price Target:
$11.50
▲(29.80% Upside)
Action:Reiterated
Date:05/09/26
The score is held back primarily by weak financial performance (no revenue, large losses, and persistent cash burn with a shrinking equity base), partially offset by strong technical uptrend signals. Corporate events are mixed: strategic refocus and financing support progress, but materially expanded share authorization increases dilution risk. Valuation is difficult to assess given negative earnings and no dividend.
Positive Factors
Strengthened clinical pipeline
Licensing a Phase 3 oncology program and expanding ELAINE-3 meaningfully improves the company's clinical asset mix and de-risks timeline to potential registration. A Phase 3 asset offers a clearer path to commercialization and partnership interest, strengthening long-term strategic positioning.
Negative Factors
Pre-revenue, large operating losses
The company remains pre-revenue with substantial recurring operating losses, meaning value depends on successful clinical outcomes and future commercialization. Persistent negative earnings consume equity and raise execution risk for patients, regulators and investors over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Strengthened clinical pipeline
Licensing a Phase 3 oncology program and expanding ELAINE-3 meaningfully improves the company's clinical asset mix and de-risks timeline to potential registration. A Phase 3 asset offers a clearer path to commercialization and partnership interest, strengthening long-term strategic positioning.
Read all positive factors
LeonaBio (LONA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$90.55M
Dividend YieldN/A
Average Volume (3M)41.47K
Price to Earnings (P/E)―
Beta (1Y)1.80
Revenue GrowthN/A
EPS Growth-16.62%
CountryUS
Employees26
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-24.15
Shares Outstanding9,393,514
10 Day Avg. Volume36,543
30 Day Avg. Volume41,474
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-0.71
Enterprise Value/Market Cap0.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.11
Enterprise Value/Ebitda-0.07
Forecast
1Y Price Target
$18.00Price Target Upside103.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.92
Revenue Forecast (FY)N/A
LeonaBio Business Overview & Revenue Model
Company Description
LeonaBio, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which ...
LeonaBio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -68.53M | -68.09M | 0.00 | 0.00 | 0.00 | -479.00K |
| EBITDA | -109.05M | -102.27M | -95.81M | -125.97M | -88.01M | -54.37M |
| Net Income | -129.41M | -105.61M | -96.94M | -117.67M | -95.64M | -54.85M |
Balance Sheet | ||||||
| Total Assets | 71.59M | 92.15M | 58.78M | 160.25M | 258.15M | 332.01M |
| Cash, Cash Equivalents and Short-Term Investments | 67.68M | 88.33M | 51.27M | 147.42M | 200.34M | 253.76M |
| Total Debt | 691.00K | 803.00K | 1.22M | 1.58M | 1.91M | 1.92M |
| Total Liabilities | 22.29M | 64.36M | 13.94M | 30.06M | 23.02M | 10.92M |
| Stockholders Equity | 49.30M | 27.79M | 44.84M | 130.19M | 235.14M | 321.08M |
Cash Flow | ||||||
| Free Cash Flow | -51.97M | -45.73M | -97.20M | -101.06M | -73.61M | -44.67M |
| Operating Cash Flow | -51.97M | -45.73M | -97.17M | -100.75M | -72.47M | -43.10M |
| Investing Cash Flow | -24.08M | -15.89M | 54.83M | 95.09M | 57.66M | -4.08M |
| Financing Cash Flow | 82.46M | 82.46M | 194.00K | 493.00K | 654.00K | 97.09M |
LeonaBio Technical Analysis
Neutral
8.86
Price Trends
9.65
Negative
7.77
Positive
6.07
Positive
Market Momentum
0.18
Positive
48.99
Neutral
40.23
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LONA, the sentiment is Neutral. The current price of 8.86 is below the 20-day moving average (MA) of 9.93, below the 50-day MA of 9.65, and above the 200-day MA of 6.07, indicating a neutral trend. The MACD of 0.18 indicates Positive momentum. The RSI at 48.99 is Neutral, neither overbought nor oversold. The STOCH value of 40.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LONA.
LeonaBio Risk Analysis
LeonaBio disclosed 89 risk factors in its most recent earnings report. LeonaBio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
LeonaBio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $90.55M | -1.42 | -381.01% | ― | ― | -16.62% | |
55 Neutral | $25.09M | -0.64 | -248.91% | ― | ― | 58.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $10.34M | -2.36 | -49.00% | ― | 11.90% | 43.46% | |
44 Neutral | $15.58M | -1.75 | -94.94% | ― | ― | 53.06% | |
| ― | $10.86M | -0.54 | -94.79% | ― | ― | 79.70% | |
43 Neutral | $23.60M | -0.15 | -83.59% | ― | ― | 19.36% |
* Healthcare Sector Average
LONA
LeonaBio
9.54
6.42
205.77%
CLRB
Cellectar Biosciences
3.14
-4.51
-58.95%
IMRN
Immuron
1.45
-0.32
-18.08%
COCP
Cocrystal Pharma
1.12
-0.59
-34.50%
BIVI
BioVie
1.42
-8.98
-86.35%
SNSE
Sensei Biotherapeutics
21.14
15.11
250.64%
LeonaBio Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
LeonaBio Updates Investors on 2025 Results and Strategy
Positive
Mar 26, 2026
On March 26, 2026, LeonaBio, Inc. released an updated investor presentation alongside full-year 2025 results, highlighting its transformation into a more focused biopharmaceutical company following a rebrand from Athira Pharma and the acquisition ...
Business Operations and StrategyPrivate Placements and FinancingShareholder Meetings
LeonaBio Expands Share Authorization to Support Future Financing
Positive
Mar 19, 2026
At a recent special meeting, LeonaBio stockholders approved the 2026 Equity Incentive Plan, replacing the 2020 plan for new grants while preserving existing awards, and authorizing up to 5.7 million new shares plus up to 1.3 million returning shar...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.